Laura J. Eccles

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu et al. · Journal of Clinical Oncology · 2022 · 381 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Thoracic Oncology · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Hierarchy of lesion processing governs the repair, double-strand break formation and mutability of three-lesion clustered DNA damage

Laura J. Eccles, Martine E. Lomax, Peter O’Neill · Nucleic Acids Research · 2009 · 75 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker et al. · European Journal of Cancer · 2024 · 73 citations

Medicine, Oncology, Pharmacology +14

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Martin Reck, Tudor–Eliade Ciuleanu, Jong-Seok Lee et al. · Journal of Thoracic Oncology · 2023 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17